Some things don’t add up about the Astrazeneca trial results.
▻https://www.covid-datascience.com/post/some-things-don-t-add-up-to-me-about-the-astrazeneca-trial-result
Le groupe demi-dose est du Brésil, l’autre du Royaume-Uni, avec des intervalles de confiance différents pour les résultats.
This discrepancy in the results between lower and higher dose is puzzling and counterintuitive. Since these results were reported, scientists have posited that somehow the lower dose might better prime the immune system, avoid an immune reaction against the viral vector used to deliver the vaccine, or might better mimic true viral exposure. It is not clear whether these have any scientific substantiation or are just speculative propositions. However, drawing any conclusions about the superiority of the “half dose” is clearly premature based on the fact that these doses were from completely different studies and thus these differences might not be fully explained by dosage differences.